Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568331 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
NCT03568331 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 375 participants.
The verdict
NCT03568331, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
Interventions
- DRUG Placebo
- DRUG Tradipitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2019-12-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03568331
The ClinicalTrials.gov registry entry for NCT03568331 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03568331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03568331 about?
NCT03568331 is a clinical study titled "Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)". This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
What is the current status of trial NCT03568331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2018-07-09. Estimated completion is 2019-12-27.
What interventions are being tested in trial NCT03568331?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT03568331?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.